Thomas Heinemann

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 6

Top Topics

Induced Pluripotent Stem Cells

Health Insurance

Top Venues

BMC medical ethics

This page only lists publications with an associated author ORCID identifier.

Publications

Johanna Risse, Merlin Krzemien, Jan Schnalke, Thomas Heinemann
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund. Gene therapy (2024)
Johanna Risse, Merlin Krzemien, Jan Schnalke, Thomas Heinemann
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund. Gene therapy 31 (7-8) (2024)
Johanna Risse, Merlin Krzemien, Jan Schnalke, Thomas Heinemann
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund. Gene therapy 31 (7-8) (2024)
Johanna Risse, Merlin Krzemien, Jan Schnalke, Thomas Heinemann
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund. Gene therapy 31 (7-8) (2024)
Sebastian Schleidgen, Hans-Georg Dederer, Susan Sgodda, Stefan Cravcisin, Luca Lüneburg, Tobias Cantz, Thomas Heinemann
Human germline editing in the era of CRISPR-Cas: risk and uncertainty, inter-generational responsibility, therapeutic legitimacy. BMC medical ethics 21 (1) (2020)
Barbara Advena-Regnery, Hans-Georg Dederer, Franziska Enghofer, Tobias Cantz, Thomas Heinemann
Framing the ethical and legal issues of human artificial gametes in research, therapy, and assisted reproduction: A German perspective. Bioethics 32 (5) (2019)